SABS – sab biotherapeutics, inc. (US:NASDAQ)
Stock Stats
News
SAB Biotherapeutics Appoints Jay Skyler, MD, to the Board of Directors [Yahoo! Finance]
SAB Biotherapeutics Appoints Jay Skyler, MD, to the Board of Directors
SAB Biotherapeutics, Inc. (NASDAQ: SABS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $6.00 price target on the stock.
SAB Biotherapeutics, Inc. (NASDAQ: SABS) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $25.00 price target on the stock.
SAB Biotherapeutics Provides SAB-142 Trial Update [Yahoo! Finance]
Form 8-K SAB Biotherapeutics, For: Apr 12
Form 8-K SAB Biotherapeutics, For: Mar 29
Form 10-K SAB Biotherapeutics, For: Dec 31
Form 8-K SAB Biotherapeutics, For: Mar 05
Form 4 SAB Biotherapeutics, For: Feb 21 Filed by: Kropotova Alexandra
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.